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Abstract
Background: Cervical dysplasia and tumorigenesis have been linked with numerous chromosomal aberrations. The
goal of this study was to evaluate 35 genomic regions associated with cervical disease and to select those which
were found to have the highest frequency of aberration for use as probes in fluorescent in-situ hybridization.
Methods: The frequency of gains and losses using fluorescence in-situ hybridization were assessed in these
35 regions on 30 paraffin-embedded cervical biopsy specimens. Based on this assessment, 6 candidate
fluorescently labeled probes (8q24, Xp22, 20q13, 3p14, 3q26, CEP15) were selected for additional testing on a set of
106 cervical biopsy specimens diagnosed as Normal, CIN1, CIN2, CIN3, and SCC. The data were analyzed on the
basis of signal mean, % change of signal mean between histological categories, and % positivity.
Results: The study revealed that the chromosomal regions with the highest frequency of copy number gains and
highest combined sensitivity and specificity in high-grade cervical disease were 8q24 and 3q26. The cytological
application of these two probes was then evaluated on 118 ThinPrep™ samples diagnosed as Normal, ASCUS, LSIL,
HSIL and Cancer to determine utility as a tool for less invasive screening. Using gains of either 8q24 or 3q26 as a
positivity criterion yielded specificity (Normal +LSIL+ASCUS) of 81.0% and sensitivity (HSIL+Cancer) of 92.3% based
on a threshold of 4 positive cells.
Conclusions: The application of a FISH assay comprised of chromosomal probes 8q24 and 3q26 to cervical
cytology specimens confirms the positive correlation between increasing dysplasia and copy gains and shows
promise as a marker in cervical disease progression.
Background
Cervical cancer is one of the three major cancer types,
along with breast and ovarian, specifically threatening
women’s health. Cervical cancer remains one of the
most common cancers among women worldwide and
the leading cause of death in many countries, especially
in developing countries [1]. PAP smear cervical cytology
screening reduced the incidence and death rate from
cervical cancer by up to 80% [2]. Recently, infection
with human papilloma virus (HPV) has been confirmed
as the major etiological cause of cervical cancer [3].
ALTS (ASCUS/LSIL Triage Study) and several other
major studies have been conducted to evaluate the use-
fulness of HPV testing for risk stratification of cervical
cancer [4,5]. Despite significant progress, the molecular
events that allow HPV infected cells to develop into
cancer cells have not been completely elucidated [6].
Chromosomal instability at a numerical or structural
level is a hallmark of malignant tumors. Deletion, dupli-
cation and amplification of various genomic regions
have been demonstrated to be present in many types of
cancers [7,8]. Fluorescent in-situ hybridization (FISH)
represents a molecular technique that allows the detec-
tion of numerical and structural abnormalities in inter-
phase cell nuclei. The goal of this study was to compare
copy number variations in critical chromosomal regions
in normal patients and in patients with varying severity
of cervical dysplasia and cervical cancer. It was impor-
tant to determine if chromosomal aberrations occur
early in tumorigenesis and whether they can be used as
the markers of cervical cancer cells. To achieve this goal
we performed a multi-step selection of FISH probes
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with a literature-based analysis of chromosomal loci
shown to be involved in the development of the cervical
cancer. We then prepared and tested candidate probes
on histological samples comprised of normal donors
and patients with CIN1, CIN 2, CIN3 and cervical can-
cer. Chromosomal loci were compared based on copy
number variations, percent positive cases in each cohort,
sensitivity and specificity parameters. The results of his-
tological evaluation indicated that 8q24 and 3q26 probes
might be useful markers of cervical cancer progression.
Therefore, 8q24 and 3q26 FISH probes were combined
into one probe set and tested on a cohort of 118 cytolo-
gical Thin-prep specimens to assess its utility.
Methods
Histological Specimens
For the initial evaluation of 35 probes, a collection of 30
de-identified slides with paraffin-embedded tissue sec-
tions from CHTN (Cooperative Human Tissue Net-
w o r k )w e r eu s e df o re v a l u a t i o n .A l lC H T Nd i v i s i o n s
have full reviews and approvals from their local IRB
(Institutional Review Board). This group consisted of 10
CIN1 (cervical intraepithelial neoplasia), 10 CIN2/CIN3,
and 10 SCC (squamous cell carcinoma) samples. For the
subsequent detailed analysis with 6 probes, a cohort of
106 de-identified paraffin-embedded tissues which con-
sisted of 21 Normal specimens, 19 CIN1 specimens, 27
CIN2 specimens, 20 CIN3 specimens, and 19 SCC spe-
cimens from the University of Texas Southwestern
(UTSW) were utilized. All histological specimens con-
sisted of ectocervical biopsies obtained during colpo-
scopic examination and were approved by the IRB at
UTSW. Histological specimens were subjected to a sec-
ond review by a qualified pathologist (R. A.) for final
diagnostic designation.
Cytological Specimens
Cytological analysis was performed on 118 residual
ThinPrep™ specimens which consisted of 19 Normal, 25
ASCUS (atypical squamous cells of undetermined signif-
icance), 35 LSIL (low-grade squamous intraepithelial
lesion), 23 HSIL (high-grade squamous intraepithelial
lesion), and 16 Cancer samples. Specimens were pre-
pared according to the ThinPrep protocol. Samples were
obtained from the UTSW and the Mayo Clinic and
were approved for research by their respective Institu-
tional Review Boards.
Probes and Formulations
A total of 35 probes were used for initial evaluation.
These 35 probes consisted of 13 centromeric probes
(CEP®) for chromosomes 1, 6, 7, 8, 9, 10, 11, 12, 15, 16,
17, 18, and X, as well as 22 locus-specific identifier
(LSI®) probes (1p31, 1q41, 2p24, 2q23, 2q33, 3p14, 3p21,
3q26, 4p15, 4p16, 5p13, 5p15, 6p21, 6q16, 7p12, 8q24,
11p15, 11p23, 11q13, 20q13, Xp22, and Xq11). Selection
of probes was based on literature review that revealed
frequent aberrations in cervical dysplasia and cancer
[9-23]. LSI and CEP probes were obtained from Vysis/
Abbott Molecular, Inc. (Des Plaines, IL). Based on the
results of the initial evaluation, a subset of 6 probes (5
LSI, 1 CEP) was generated. CEP3 was included for the
purpose of evaluating true amplification of arm versus
polyploidy. The probes included for subsequent evalua-
tion were combined into two probe sets. The first probe
set consisted of 8q24 (SpectrumGold™), 20q13 (Spec-
trumRed™), Xp22 (SpectrumGreen™), and CEP15 (Spec-
trumAqua™). The second probe set included 3p14
(SpectrumGreen), 3q26 (SpectrumGold), and CEP3
(SpectrumAqua). For cytological analysis, the probe set
consisted of 8q24 (SpectrumGold) and 3q26
(SpectrumGreen).
Histological Sample Pretreatment and Hybridization
Histological specimens were pretreated three times in
Hemo-De (Scientific Safety Solvents) for 5 minutes each
at room temperature followed by two 1-minute rinses in
100% ethanol (EtOH) at room temperature, incubation
in 45% formic acid/0.3% hydrogen peroxide for 15 min-
utes at room temperature and then rinsed in deionized
water for 3 minutes. Slides were then incubated in pre-
treatment solution (Abbott Molecular, Inc.) at 80°C for
10 minutes, rinsed for 3 minutes in deionized water,
incubated 5-10 minutes in proteinase K solution at
37°C, and rinsed again for 3 minutes in deionized water.
Slides were dehydrated for 1 minute each in 70% EtOH,
85% EtOH, and 100% EtOH and then air dried. Ten
microliters of each respective probe hybridization mix
(LSI® buffer, blocking DNA, labeled probes) were added
to the specimens, a coverslipa p p l i e d ,a n ds e a l e dw i t h
rubber cement. Slides were codenatured for 5 minutes
at 72°C and hybridized for 16 hours at 37°C on a
HYBrite (Vysis/Abbott Molecular, Inc.). Following hybri-
dization, coverslips were removed and slides were
washed in 2X SSC/0.3% NP-40 at 73°C for 2 minutes
and subsequently in 2X SSC/0.1% NP-40 for 1 minute
at room temperature. Ten microliters of DAPI I coun-
terstain were placed on the slide and a coverslip applied.
Cytological Sample Pretreatment and Hybridization
Cytological specimens were pretreated in 72°C 2X SSC
for 2 minutes followed by a 10 minute incubation in
pepsin solution (0.5 mg/ml in 10 mM HCl) at 37°C.
Slides were then rinsed in 1X PBS for 5 minutes, fixed
in a 1% neutral-buffered formalin solution for 5 minutes
and rinsed again in 1X PBS for 5 minutes. Dehydration
of slides was performed via an ethanol series: 1 minute
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lowed by air-drying. Ten microliters of the probe hybri-
dization mix (LSI® buffer, blocking DNA, labeled probes)
were added to the specimens, slides were coverslipped,
and sealed with rubber cement. Slides were codenatured
for 2 minutes at 72°C and hybridized for 16 hours at
37°C on a HYBrite (Vysis/Abbott Molecular, Inc.). Fol-
lowing hybridization, coverslips were removed and slides
were washed in 2X SSC/0.3% NP-40 at 73°C for 2 min-
utes and subsequently in 2X SSC/0.1% NP-40 for 1 min-
ute at room temperature. Ten microliters of DAPI I
counterstain were placed on the slide and a coverslip
applied.
FISH Evaluation - Histological Specimens
Following hybridization, slides were evaluated using
fluorescence microscopy with SpectrumGold, Spectru-
mOrange™, SpectrumRed, SpectrumGreen, and Spectru-
mAqua fluorescence filters (Vysis/Abbott Molecular,
Inc., Des Plaines, IL). Tissue orientation was identified
and the epithelial layer of the tissue was enumerated.
Cells were considered to be chromosomally abnormal if
they possessed three or more signals. Enumeration was
completed upon identification of 25 abnormal cells or
complete analysis of the epithelial layer. Samples were
considered positive if 4 or more chromosomally abnor-
mal cells were found for each probe being evaluated.
FISH Evaluation - Cytological Specimens
Following hybridization, slides were evaluated using
fluorescence microscopy with SpectrumGold\and Spec-
trumRed fluorescence filters. Specimens were enumer-
ated methodically, beginning with one corner of the
cellular area, and enumerating each consecutive field of
view from top to bottom and left to right. Cells were
considered to be chromosomally abnormal if individual
probes presented three or more signals. Enumeration
was completed upon identification of 25 abnormal cells
or the complete analysis of the cellular area. If 25 abnor-
mal cells were recorded before completion of the entire
area, the fraction of slide that was enumerated was
recorded and the total number of abnormal cells per
slide was calculated using this fraction.
Statistical Analysis
Statistical analysis was performed using computer
assisted correlation analysis with JMP Statistical Discov-
ery Software (SAS; Cary, NC).
Results
Initial Probe Evaluation
The initial assessment of probes involved in cervical dis-
ease progression was executed on a limited set of sam-
ples (10 CIN1, 10 CIN2/3, 10 SCC specimens). The
evaluation of the 35 potential probes was based on the
frequency of aberrations observed for each histological
category (CIN1, CIN2/3, SCC). An initial compilation
and analysis of the enumeration data revealed that copy
gains were significantly more prevalent than copy losses
(Table 1); hence, we decided to focus our analysis
mainly upon copy gains. In selecting the best candidate
probes, we wanted to identify probes that revealed the
highest frequency of gains in both the CIN2/3 and SCC
categories, while maintaining a low frequency of copy
gain detection in the CIN1 category. Using histology as
the gold standard, the probes would exhibit copy num-
ber changes in 100% of cancer cases and 100% of CIN2/
3 cases. Moreover, copy gains for the CIN1 category
should be as close to 0% as possible. Based on this
method of probe selection, the probes were initially
sorted according to highest frequency of copy gains in
cancer cases. For each probe we determined the percent
of samples found positive based on our criteria (see
methods) for groups of cancer and CIN2/3 cases (see
Table 1). A threshold of 70% positive cases for cate-
gories of cancer and CIN2/3 was selected for exclusion
of non-viable candidate probes. This threshold was
determined to be an effective level of exclusion based
on the limited size of the sample set. Of the 35 probes
evaluated, 32 probes demonstrated copy gains in more
than 70% of cancer samples whereas 12 probes were
able to detect copy gains in at least 70% of CIN2/3
lesions.
The final criterion for probe selection based on copy
gains was a low percentage of copy gain detection in the
CIN1 category in combination with highest percentages
of copy gain detection for CIN2/3 and Cancer. This eva-
luation generated a set of 5 probes that detected copy
gains in ≤ 10% of CIN1, and ≥ 70% of CIN2/3 and Can-
cer lesions: 8q24, 20q13, Xp22, 1p31, and CEP15 probes.
Two of the probes - Xp22 and 1p31 - were nearly iden-
tical in overall performance across the 3 categories in
this phase of our study. Based on the similarity in per-
formance in high-grade/cancer lesions between the two
probes, only one of these probes was retained for further
evaluation - Xp22. 1p31 was excluded from subsequent
assessment.
It is necessary to note that in our study, 3q26 was
found to be excellent at detecting both cancer and high-
grade lesions (CIN2/3), however, it did not meet our cri-
teria established for CIN1 cases that required to detect
copy gains in ≤ 10% of samples (3q26 detected gains in
30% of CIN1 cases). However, due to the frequency of
implication of 3q26 in disease progression from this
assessment as well as published data [24-26], this probe
was retained for subsequent probe evaluation studies.
Additionally, CEP3 was also added to monitor amplifica-
tion and deletion for the aforementioned locus.
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their significance in progression of cervical dysplasia.
The data from the 35 probes was analyzed based on
percentage of samples with copy loss observed in cancer
(Table 1). Only one probe, 3p14, was able to detect
copy losses in 80% of cancer samples. 7 probes were
only able to detect copy losses in 10-20% in the same
set of samples. In detecting CIN2/3 lesions, 3p14 was
able to detect copy losses in 20% of these samples and 4
other probes were able to detect copy losses in 10-11%
of cases (see Table 1). Results show that in the CIN1
category the percent of cases showing copy number loss
Table 1 Percent probe copy gains and losses for each histological category (CIN1 - n = 10; CIN2/3 - n = 10; SCC -
n = 10)
% of Samples with Probe Copy Gains % of Samples with Probe Copy Loss
Probe CIN
a1 CIN
a2-3 SCC
b Probe CIN
a1 CIN
a2-3 SCC
b
8q24 0 80 100 3p14.2 20 20 80
3q26 30 80 100 2q33-q34 11 11 20
5p13 30 80 100 Xq11-q12 22 0 20
5p15.2 40 80 100 3p21-p23 11 0 18
CEP
c8 30 78 100 Xp22.3 20 0 11
CEP
cX 50 75 100 1q41 0 0 10
CEP
c10 18 70 100 7p12.3-p12.1 0 0 10
CEP
c16 20 60 100 CEP
c71 0 0 1 0
CEP
c12 10 56 100 2q23-q37 0 10 0
CEP
c6 10 50 100 6q16.3-q21.3 0 10 0
CEP
c9 0 44 100 6p21.2 10 10 0
CEP
c11 20 44 100 8q24.12-24.13 0 0 0
CEP
c1 13 43 100 CEP
c16 0 0 0
CEP
c17 10 40 100 20q13.2-q13.3 0 0 0
CEP
c7 30 60 91 CEP
c15 0 0 0
20q13.2-q13.3 10 80 90 2p24.1 0 0 0
CEP
c15 0 70 90 CEP
c18 0 0 0
2p24.1 20 67 90 11p15.5 0 0 0
1q41 9 60 90 11q13 0 0 0
7p12.3-p12.1 10 60 90 1p31.1.1 0 0 0
Xq11-q12 11 60 90 4p16.3 0 0 0
CEP
c18 11 60 90 11q23 0 0 0
11q13 27 60 90 4p15.3 0 0 0
11p15.5 18 50 90 3q26 10 0 0
11p23 45 30 90 5p13 10 0 0
6q16.3-q21.3 10 40 82 5p15.2 10 0 0
6p21.2 0 10 82 CEP
c81 0 0 0
Xp22.3 0 70 80 CEP
cX1 0 0 0
1p31.1.1 9 70 80 CEP
c12 10 0 0
4p15.3 20 50 80 CEP
c11 10 0 0
4p16.3 30 50 80 CEP
c91 0 0 0
2q23-q37 20 30 80 CEP
c17 10 0 0
3p21-p23 14 86 55 CEP
c61 0 0 0
2q33-q34 33 44 50 CEP
c11 3 0 0
3p14.2 10 60 9 CEP
c10 18 0 0
a = cervical intraepithelial neoplasia
b = squamous cell carcinoma
c = centromeric probe
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Therefore, only 3p14 was retained for subsequent inves-
tigation in a larger sample cohort.
Evaluation of probes based on mean signals per cell
In order to select the best probes for detecting high-
grade disease we compared probe gains and losses for
8q24, CEP15, Xp22, 20q13, 3p14, 3q26, and CEP3 on a
larger set of biopsy specimens. Enumeration data from
106 specimens was analyzed according to the mean
number of signals per cell for each histological cate-
gory evaluated: Normal (n = 21), CIN1 (n = 19), CIN2
(n = 27), CIN3 (n = 20), and SCC (n = 19). The data
is summarized in Figure 1. As expected, the mean of
signals for specimens diagnosed as Normal was
approximately 2, ranging from 1.98 to 2.04. For CIN1
samples the mean of signals showed more variation
among specimens, however was still relatively close to
2. The lowest observed mean for CIN1 samples was
2.06 (CEP15) followed by 2.09 (Xp22). Subsequently,
20q13 had a mean of 2.12 signals, and 3p14 and CEP3
had a mean of 2.13 and 2.16 signals, respectively. The
two probes having the highest mean of signals for the
CIN1 category were 8q24 with 2.21 signals and 3q26
with 2.25 signals. The CIN2 category revealed a much
larger discrepancy between the candidate probes. 3p14
and CEP15 had a mean of signals of 2.13 and 2.22,
respectively, whereas, 20q13, 3q26, and 8q24 revealed
probe signal means of 2.43, 2.48, and 2.63, respectively.
CEP3 and Xp22 were both found to have a mean of
2.32 signals. Further stratification of probes was seen
in the CIN3 specimens. The two probes with the high-
est mean for copy numbers were 8q24 and 3q26 (2.95
and 3.03, respectively). The next two probes showed
an appreciably lower mean: CEP3 with 2.64 average
copies and 20q13 with 2.56 average copies. The
remaining four probes had average copy numbers of
2.50, 2.38, and 2.37 (Xp22, CEP15, and 3p14,
respectively).
In cancer cases, 3q26, 8q24, 20q13 and Xp22 revealed
an increase in mean copy number. CEP15 average copy
number did not change. However, a decrease in copy
number was observed for CEP3 and more importantly, a
noteworthy decrease observed for 3p14. The mean copy
number for this probe was found to be 1.32 thereby
revealing copy losses as opposed to gain in the cancer
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Figure 1 Mean number signals per specimen for each probe across all histological categories.
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the previously obtained results.
Change of mean copy number between categories
To give further insight into the differences between
probes amongst all the histological categories, analysis
was performed according to percent change of mean
copy number (see Figure 2). Based on the total copy
number percent change from Normal to Cancer speci-
mens, 4 probes have shown an increase greater than
40%: 8q24 (73.7%), 20q13 (66.9%), 3q26 (47.1%), and
Xp22 (43.8%). The increase in copy gains from the Nor-
mal to the CIN1 category was relatively minor with all
but one probe (3q26) below 10%. These four probes
were also capable of revealing copy gains between CIN1
and CIN2 histological categories with a percent change
range of 11.0% to 19.0%. The performance of these four
probes varied in high-grade lesions (CIN2-3) and cancer.
3q26 demonstrated the highest percent change from
CIN2 to CIN3, 22.2%, followed by 8q24 (12.2%), Xp22
(7.8%), and 20q13 (5.3%). The change from CIN3 to
cancer was best detected by 20q13 (41.4%), 8q24
(34.2%), and Xp22 (21.6%). 3q26 showed a lesser ability
to detect the CIN3 to cancer progression with a 3.3%
change. 3p14 revealed overall copy losses when % total
change and % change from CIN3-SCC were evaluated.
Threshold Determination
Using the data obtained from enumeration, thresholds
ranging from 1 to 10 aneusomic cells were evaluated via
receiver operating characteristic (ROC) curves to deter-
mine the optimum threshold for evaluation of probes.
The results from this analysis are displayed in Figure 3.
Each probe plot consists of 10 data points which repre-
sent the thresholds from 1 to 10 aneusomic cells (from
right to left). ROC curves simultaneously evaluate both
the sensitivity and specificity of a probe for each thresh-
old. For ROC curve analysis, sensitivity was defined as
percent positivity for CIN2 and CIN3 specimens and
specificity was defined as percent positivity for Normal
and CIN1 specimens. The curves shown in Figure 3
reveal that typically, with thresholds of 1 or 2 cells, sen-
sitivity is high but specificity is low. Conversely, with
thresholds ranging from 6 to 10 cells, most probes have
high specificities but relatively low sensitivities. The
remaining range of thresholds (3-5 cells) exhibit accep-
table levels of both sensitivity and specificity for most of
the probes being evaluated. Based on the ROC curve
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Figure 2 Percent change of mean probe copy numbers between histological categories. Values above zero represent positive values
(gains) and values below zero represent negative values (losses).
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Page 6 of 12results, we selected a 4 cell threshold for further probe
analyses.
% Positivity per Histological Category
The results of the percent positivity analyses using the 4
positive cells threshold are summarized in Table 2. Four
probes demonstrated an excellent ability to detect SCC
in the sample cohort: 8q24, 3q26, Xp22, and 20q13
(100%, respectively). For the CIN3 category, 8q24 and
3q26 were able to detect 100% and 95% of cases, respec-
tively, while Xp22 and 20q13 performance declined (80%
and 70% of cases detected for each probe). 8q24
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Figure 3 Receiver Operating Characteristic Curve (ROC) for threshold determination using histological samples. The ROC analysis utilized
1 to 10 cells (from right to left on the graph, respectively) for curve determination.
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with a positivity rate of 96.3%; concurrently, 3q26 had a
positivity rate of 81.5%. The positivity rate continued to
decrease with 20q13 and Xp22 probes with 74.1% and
70.4%, respectively. CEP15 revealed the lowest level of
performance among all the probes for both the high-
grade and cancer categories, including the respective
combined categories.
A low percent positivity rate for Normal and low-grade
cervical lesions (CIN1) was also an important factor for
probe evaluation since low values indicate good specifi-
city. For the Normal category, the percent positivity rate
for all probes was low ranging from 0% to 4.8% (see
Table 2). The percent positive rate for the CIN1 category
displayed a higher diversity amongst the probes, ranging
from 10.5% (Xp22 & CEP15) to 31.6% (3q26).
Percent positivity analysis was also performed for
probes ratio using CEP3 to analyze amplification of the
chromosome arm relative to the respective chromosome
(Table 2). The ratio of 3q26 gain/CEP3 gain ≥ 1w a s
negative for Normal specimens (0%) and displayed rela-
tively low positivity for CIN1 specimens (21.1%). The
performance was marginal for CIN2 samples (51.9%
positivity) and improved for the CIN3 and SCC cate-
gories (75% and 89.5% positivity). Although an improve-
ment was seen in evaluating the CIN3 and SCC
categories, the ratio of 3q26 to CEP3 did not exceed the
individual performance of 3q26.
Since 3p14 displayed a higher frequency of losses in
cancer cases combined with a relatively low frequency
of gains in high-grade dysplasia, the percent positivity of
samples with copy loss was evaluated. Percent positivity
(using loss rather than gain) for the Normal and CIN1
categories was found to be low (9.5% and 0%, respec-
tively), indicating good specificity for 3p14 probe. In
CIN2 and CIN3 specimens percent positivity was still
low (33.3% and 30.0%). A dramatic increase was
observed for percent positivity in the SCC category
(89.5%) using 3p14 losses as the criterion. The overall
percent positivity rates for high-grade and high-grade/
cancer specimens analyzed with 3p14 loss were 31.7%
and 50.9%. Based on these moderate positivity rates,
3p14 was determined to be an inadequate probe for
detecting high-grade dysplasia/cancer and was excluded
from subsequent analysis.
The ratio of 3p14 loss to CEP3 revealed some differ-
ences in performance when compared to 3p14 loss
alone (see Table 2). Percent positivity for Normal cases
was the same for both 3p14 loss alone and the 3p14
loss/CEP3 ratio (9.5%), however, 3p14 loss did not
detect any CIN1 cases whereas the 3p14 loss/CEP3 ratio
detected a few (5.6%). However, performance of the
3p14 loss/CEP3 ratio vers u s3 p 1 4l o s sw a sv a s t l y
improved for CIN2 and CIN3 categories (63.0% and
75.0% versus 33.3% and 30.0%, respectively). For the
SCC specimens, the 3p14 loss/CEP3 ratio also showed
improvement over 3p14 loss alone (100% vs. 89.5%).
Overall, based on the histological analyses, 8q24 and
3q26 were determined to show the highest degree of
copy number changes as measured by the mean value
amongst all the probes. They showed best sensitivity to
copy number changes from CIN2 to CIN3 categories
and from CIN3 to Cancer categories. And finally, they
had the best performance in identifying high-grade
lesions and cancer as well as the ability to distinguish
low-grade and high-grade lesions.
Table 2 Percent positivity analyses for each probe across all histological categories (Normal - n = 21; CIN1 - n = 19;
CIN2 - n = 27; CIN3 - n = 20; SCC - n = 19)
Threshold = 4 Cells % Positive cases
Normal
% Positive cases
CIN
a1
% Positive cases
CIN
a2
% Positive cases
CIN
a3
% Positive cases
SCC
b
8q24 gain 4.8 26.3 96.3 100.0 100.0
3q26 gain 0.0 31.6 81.5 95.0 100.0
Xp22 gain 0.0 10.5 70.4 80.0 100.0
20q13 gain 0.0 21.1 74.1 70.0 100.0
CEP
c3 gain 0.0 15.8 66.7 75.0 68.4
CEP
c15 gain 4.8 10.5 63.0 65.0 68.4
Ratio 3q26/CEP
c3>
1
0.0 21.1 51.9 75.0 89.5
Ratio
3p14/CEP
c3<1
9.5 5.6 63.0 75.0 100.0
3p14 < 1 loss 9.5 0.0 33.3 30.0 89.5
a = cervical intraepithelial neoplasia
b = squamous cell carcinoma
c = centromeric probe
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Page 8 of 12Cytological Analysis of 8q24 and 3q26 probe
performance
Based on the probe performance shown for histological
samples, 8q24 and 3q26 probes were formulated into
one probe set for testing and assessing their utility for
cytology specimens. 118 cytological specimens were
enumerated and the data was analyzed according to
mean number of abnormal cells per cytological category
for 8q24, 3q26, and 8q24 or 3q26 combined (see Figure
4). The numbers of abnormal cells detected by 8q24,
3q26, and their combination correlated with increasing
grades of dysplasia. As presented in Figure 4, both
probes exhibited good performance in detecting abnor-
mal cells for all cytological categories, although some
slight quantitative differences between the probes were
observed, particularly in HSIL samples. The use of either
8q24 or 3q26 in combination to determine cellular
abnormality was found to be the best option for all
cytological categories, further confirming a complemen-
tary effect of these probes. Based on these results using
the criterion of either 8q24 or 3q26 copy gains to
determine cell abnormality would provide the best over-
all capability in detecting aneusomy.
In order to determine the sensitivity and specificity of
using the aforementioned criterion, ROC curves were
utilized similarly to our previous analysis of histological
samples. NIL, ASCUS, and LSIL samples were used to
represent specificity and HSIL and Cancer samples were
used to determine sensitivity. The enumeration data was
evaluated at threshold values of 1, 5, 10, 15, 20, 25, 30,
35, 40, 45, and 50 abnormal cells. The ROC curve
revealed an inflection point at the 30 cell threshold
threshold, indicating the best overall performance for
sensitivity and specificity (data not shown). Using the 30
cell threshold, sensitivity and specificity were found to
be 92.3% and 81.0%, respectively. These results clearly
indicate a potential of a FISH based assay for detecting
abnormal cells in cervical cytology specimens.
Discussion
In this study we described the assessment of FISH
probes that were found to be highly associated with
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Figure 4 Mean number of abnormal cells for each cytological category using 3q26 or 8q24, 8q24, and 3q26. The 3q26 or 8q24
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cells found positive with 8q24, and the 3q26 Abnormal column represents all cells that were found positive by 3q26.
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Page 9 of 12progression of cervical dysplasia. The initial selection
process evaluated the frequency of gains and losses of
35 probes of centromeres and specific loci that were
identified in literature as having some implication in
cervical disease [9-23]. Preliminary evaluation focused
on the highest frequencies of gains/losses in the SCC
category, followed by CIN2/3, combined with the lowest
frequency of gains and losses in CIN1. The result of this
analysis yielded a smaller subset of probes: 8q24, 20q13,
CEP15, and Xp22. 3q26 also exhibited good perfor-
mance for high-grade and cancer cases and was further
evaluated in the larger set of biopsy samples. Only one
probe - 3p14 - revealed substantial losses that, in combi-
nation with previously published data [13,19,21] war-
ranted its retainment for further testing.
Our subsequent comprehensive evaluation distin-
guished 2 probes that exhibited the highest correlation
with high-grade lesions, 8q24 and 3q26. These two
probes had the highest signal means for CIN2 and CIN3
cases, respectively (Figure 2). Figure 3 illustrates the
overall signal mean changes between categories and
shows that the combination of 8q24 and 3q26 offers
comprehensive coverage from CIN2 to SCC. 8q24 excels
in detecting CIN2 and SCC, whereas 3q26 outperforms
all other probes in detecting CIN3 lesions. This is con-
sistent with several reports where 3q26 locus was
demonstrated to be frequently associated with cervical
dysplasia and transition to invasive cancer [24-27].
Another probe that displayed good performance in
SCC as well as CIN2 samples, as evidenced by signal
mean and % signal mean change was 20q13. This chro-
mosomal region comprises several important genes,
including Aurora kinase A, which was implicated in the
development of aneuploidy through deregulation of cen-
trosome formation [28-30]. Increased copy number of
20q13 region was shown to be associated with both
squamous cell carcinoma and adenomacarcinoma of the
cervix [22]. However, this probe was not as effective at
detecting CIN3 samples as 3q26, which are of critical
importance in cervical disease progression, predomi-
nantly for underlying lesions not discovered through
cytological analysis. Additionally, when compared to
8q24, 20q13 performance, although similar, was found
to be consistently lower in overall signal mean as well as
percent change of means from low to high-grade
categories.
CEP15 was the only centromeric probe that passed the
initial criteria for selection and thus was used for further
testing. This probe clearly did not perform as well as
perceived based on the initial screening. The change in
overall signal mean for CEP15 across all categories was
limited (2.01 to 2.39, Normal to SCC) and the percent
change was less than that of the aforementioned probes.
The poor performance of centromeric probes when
compared with locus specific arm probes perhaps indi-
cates that copy number changes in the chromosomal
arm and bands occur earlier than whole genome
polyploidisation.
The disparity in performance among the probes was
clearly evident in percent positivity analysis for histology
samples (Table 2). 8q24 and 3q26 were the most valu-
able probes for detecting high-grade (CIN2/3) and SCC
lesions. Using a 4 cell threshold, 8q24 detected 98.8% of
high-grade and cancer cases followed by 3q26 with
92.2%. Among the other probes tested, Xp22 and 20q13
performance in high-grade and cancer cases was similar.
Deletions of several genetic loci have previously been
implicated in cervical dysplasia and cancer. The fre-
quency of copy loss, as evidenced in our study, was
shown to have a minimal correlation with the high-
grade categories of dysplasia. For instance, 3p14 probe
loss was observed in 33.3% of CIN2 samples and 30.0%
of CIN3 samples, whereas 89.5% of SCC samples dis-
played a 3p14 deletion. The poor performance of 3p14
in high-grade dysplasia and excellent performance in
cancer leads us to believe that the loss of 3p14 locus,
which comprises the FHIT gene, is a late event in cervi-
cal disease [19].
The positivity rate for CIN1 specimens using 8q24
and 3q26 probes was found to be 15.5% and 15.8%,
respectively; it was significantly lower for Normal
cases (4.8% and 0%, respectively) indicating good spe-
cificity. It is possible that CIN1 cases determined to
be positive by 8q24 and 3q26 may in fact be harboring
molecular changes indicative of disease progression
that were not visualized during histological analysis. In
fact, several studies have demonstrated that a propor-
tion of patients with ASCUS and LSIL may progress
to higher grade of dysplasia and even cancer [31-33].
I ti st h e r e f o r ef e a s i b l et h a t8 q 2 4a n d3 q 2 6m a yh a v e
an advantage of earlier detection of severe dysplasia
when compared to the other probes evaluated as evi-
denced by percent positivity rates of 20q13 and Xp22
for the CIN1 category (Table 2). Indeed, 3q26 has
already been shown to have prognostic value in identi-
fying a high-progression risk in low-grade lesions [26].
It is possible that the increased sensitivity of 8q24 and
3q26 probes may provide further stratification and
earlier identification of increased dysplasia in CIN1
patients.
The application of 8q24 and 3q26 probes to cytologi-
cal samples revealed a strong correlation between aneus-
omy and increasing cytological diagnosis. The ability of
these probes to detect copy gains in ASCUS and LSIL
samples is significant in that molecular changes possibly
representing underlying high-grade dysplasia can be dis-
covered without the use of invasive procedures. The use
of 3q26 as persistence-progression indicator has
Policht et al. BMC Cancer 2010, 10:432
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Page 10 of 12previously been shown [34] and may aid in avoiding
unnecessary colposcopies and biopsies, particularly in
women who do not present obvious high-grade dyspla-
sia. Moreover, the use of 3q26 has been shown to accu-
rately distinguish between HSIL and LSIL [35]. The
inclusion of 8q24 in our study for cervical screening has
shown an increase in both sensitivity and specificity
when compared to using either 8q24 or 3q26 alone for
ASCUS, LSIL, and HSIL specimens. In normal speci-
mens both probes identified cells with low levels of
abnormality, which can be attributed to several factors
including inflammatory/reactive changes and cells in the
process of division, presenting tetrasomic signal counts.
Although these cells were detected utilizing 8q24 and
3q26, a cutoff of 30 abnormal cells prevented these cells
from impacting the specificity of these probes. There-
fore, our findings in cytological samples are in accord
with our histological results and further support the uti-
lity of 8q24 and 3q26 as important markers in detecting
cervical disease.
Conclusions
It is clear that several genes are involved in cervical dys-
plasia and cancer [36]. In our study, we identified that
gene amplification is much more frequently encountered
in cervical dysplasia compared to gene loss. Only one
probe, 3p14, exhibited significant losses, which were
mainly detected in cancer cases. Conversely, several
probes demonstrated substantial rates of amplification
in high-grade dysplasia and cancer. However, based on
all the analyses presented, 8q24 and 3q26 clearly outper-
form the other probes tested in detecting high-grade
dysplasia and cancer. Moreover, 8q24 and 3q26 probes
may have a utility as prognostic markers in cervical dys-
plasia, particularly in underlying high-grade lesions.
Additional studies need to be performed to establish a
greater confidence in the clinical utility of 8q24 and
3q26 FISH probes as prognostic markers.
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